<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthroplast Today</journal-id><journal-id journal-id-type="iso-abbrev">Arthroplast Today</journal-id><journal-id journal-id-type="pmc-domain-id">3043</journal-id><journal-id journal-id-type="pmc-domain">artd</journal-id><journal-title-group><journal-title>Arthroplasty Today</journal-title></journal-title-group><issn pub-type="epub">2352-3441</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11035087</article-id><article-id pub-id-type="pmcid-ver">PMC11035087.1</article-id><article-id pub-id-type="pmcaid">11035087</article-id><article-id pub-id-type="pmcaiid">11035087</article-id><article-id pub-id-type="pmid">38654888</article-id><article-id pub-id-type="doi">10.1016/j.artd.2024.101372</article-id><article-id pub-id-type="pii">S2352-3441(24)00057-8</article-id><article-id pub-id-type="publisher-id">101372</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Active Amphetamine Abuse in Total Hip Arthroplasty Carries Increased Risk for Postoperative Surgical and Medical Complications</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Kelly</surname><given-names initials="M">Mackenzie</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Huff</surname><given-names initials="T">Thomas</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Schabel</surname><given-names initials="K">Kathryn</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Yoo</surname><given-names initials="J">Jung</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Lieberman</surname><given-names initials="E">Elizabeth</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Kagan</surname><given-names initials="R">Ryland</given-names></name><degrees>MD</degrees><email>kagan@ohsu.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>a</label>Department of Orthopaedics and Rehabilitation, Oregon Health &amp; Science University, Portland, OR, USA</aff><aff id="aff2"><label>b</label>Orthopedic + Fracture Specialists, Portland, OR, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. Tel.: +1 503 494 5649. <email>kagan@ohsu.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>6</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>16</day><month>4</month><year>2024</year></pub-date><volume>27</volume><issue-id pub-id-type="pmc-issue-id">458235</issue-id><elocation-id>101372</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2023</year></date><date date-type="rev-recd"><day>23</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>3</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>23</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-25 08:25:12.997"><day>25</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background</title><p>The impact of amphetamine abuse on total hip arthroplasty (THA) outcomes has yet to be studied. As the rates of methamphetamine abuse continue to rise, understanding the risk profile of this population is imperative. This study aims to determine the risk of major surgical and medical complications for those with amphetamine abuse undergoing THA, with the hypothesis that amphetamine abuse carries increased risk.</p></sec><sec><title>Methods</title><p>A retrospective review was performed with all-claims data files of a large national database querying International Classification of Disease, tenth revision, procedure codes identifying 333,038 primary THA, and 1027 with active amphetamine abuse. Medical and surgical complications including infection, dislocation, implant failure, periprosthetic fracture, and revision, as well as length of hospital stay and 90-day readmission rate, were identified. Univariate analysis compared rates of dependent outcomes. To account for independent variables, logistic regression was performed using age, Charlson comorbidity index, sex, obesity, tobacco use, and alcohol use. The results were presented as odds ratios (OR) and <italic toggle="yes">P</italic> values with significance set at &lt;0.05.</p></sec><sec><title>Results</title><p>Patients with active amphetamine abuse carried an increased risk of dislocation (OR 1.82, <italic toggle="yes">P</italic> &#8804; .001), infection (OR 2.37, <italic toggle="yes">P</italic> &#8804; .001), mechanical complications (OR 1.64, <italic toggle="yes">P</italic> &#8804; .001), periprosthetic fracture (OR 1.53, <italic toggle="yes">P</italic> &#8804; .05), revision (OR 1.70, <italic toggle="yes">P</italic> &#8804; .001), 90-day readmission (OR 1.79, <italic toggle="yes">P</italic> &#8804; .001), as well as medical complications (1.43, <italic toggle="yes">P</italic>&#160;= .02) compared to those without documented amphetamine abuse.</p></sec><sec><title>Conclusions</title><p>Patients with amphetamine abuse are at increased risk of postoperative surgical and medical complications following THA. We recommend consideration of these risks prior to primary THA in this patient population.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Methamphetamine</kwd><kwd>Amphetamine abuse</kwd><kwd>Total hip arthroplasty</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Methamphetamine is an illicit stimulant, which is on the rise in the United States [<xref rid="bib1" ref-type="bibr">1</xref>]. From 2015 to 2019, methamphetamine abuse increased by 43% with an estimated annual hospital economic burden of $2.17 billion in 2015 alone [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>]. As usage rate increases alongside an aging US population, so has the age of users, with one study showing 34% of a level 1 trauma center&#8217;s methamphetamine-abusing orthopaedic trauma population consisting of patients &#8805;55 years of age, with the elderly use rate quadrupling over time from 2009 to 2018 [<xref rid="bib3" ref-type="bibr">3</xref>]. As the rates of amphetamine abuse rise in an aging population, counseling patients regarding risks following arthroplasty while consuming amphetamines with an emphasis on cessation is of utmost importance.</p><p id="p0015">While there is a paucity of research among arthroplasty literature, amphetamine abuse, in particular methamphetamine abuse has been shown to lead to adverse surgical and medical outcomes particularly within orthopaedic trauma literature. One retrospective study from a single level 1 trauma institution found a 3-fold increase in reoperation rates for patients who abuse methamphetamine undergoing open reduction and internal fixation for acetabular fracture [<xref rid="bib4" ref-type="bibr">4</xref>]. Research has shown that patients with amphetamine abuse disorder have higher resource utilization, with increased cardiovascular perioperative complications, longer length of stay, and higher in-hospital mortality and readmission rate [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>]. With methamphetamine and illicit amphetamine abuse pervasive and rising among elderly orthopedic populations, understanding the impact among arthroplasty outcomes is of utmost importance however remains unknown [<xref rid="bib3" ref-type="bibr">3</xref>].</p><p id="p0020">The purpose of this study is 4-fold: (1) to determine the prevalence of amphetamine abuse among the primary total hip arthroplasty (THA) population; (2) to determine the risk of major surgical and medical complications following primary THA for osteoarthritis in patients with amphetamine abuse compared to those without amphetamine abuse; (3) to identify the risks of polysubstance use and its impact on medical and surgical complications; and (4) to evaluate the risk of medical and surgical complications for those with amphetamine abuse in remission compared to those without amphetamine abuse. We hypothesized that patients with amphetamine abuse are more likely to engage in polysubstance use and have higher rates of surgical and medical complications following THA compared to patients without amphetamine abuse, with risks that persist when in remission.</p></sec><sec id="sec2"><title>Material and methods</title><p id="p0025">A cross-sectional cohort study was performed by querying International Classification of Disease, tenth revision (ICD-10), procedure codes from the PearlDiver database from 2015 to 2020 for THA indicated for osteoarthritis. Active amphetamine abuse, as well amphetamine abuse in remission was identified. Demographic data including age, sex, obesity, tobacco use, alcohol use, and Charlson comorbidity index were collected. Major surgical and medical complications including infection, dislocation, implant failure, periprosthetic fracture, and revision were then identified by ICD-10 diagnosis codes, as well as length of hospital stay and 90-day readmission rate (<xref rid="tblS1" ref-type="table">Appendix 1</xref>).</p><p id="p0030">Statistical analysis was performed using R (R Core Team, 2021). Descriptive statistics were calculated for demographic variables (<xref rid="tbl1" ref-type="table">Table&#160;1</xref>). Complication rates were described as a proportion of the entire cohort. Univariate analysis compared rates of dependent outcomes. Differences in complication rate based on continuous variables (age and Charlson comorbidity index) and categorical variables (sex and obesity diagnosis) were analyzed using t-tests and chi-square tests, respectively. To account for other independent variables, logistic regression analysis was done using age, Charlson comorbidity index, sex, obesity, tobacco use, and alcohol use as additional independent covariates. The results were presented as odds ratios (OR) and <italic toggle="yes">P</italic> values reported, with significance set at &lt;0.05.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table&#160;1</label><caption><p>Patient characteristics and complications of nonstimulant users, stimulant users, and those in remission undergoing primary total hip arthroplasty.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Variable</th><th colspan="1" rowspan="1">Nonstimulant</th><th colspan="1" rowspan="1">Stimulant</th><th colspan="1" rowspan="1">Remission</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">331,878</td><td colspan="1" rowspan="1">1027</td><td colspan="1" rowspan="1">133</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Age [mean (SD)]</td><td colspan="1" rowspan="1">66.77 (10.5)</td><td colspan="1" rowspan="1">55.36 (11.2)</td><td colspan="1" rowspan="1">53.71 (9.5)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Sex [n (%)]</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td colspan="1" rowspan="1">141,194 (42.5)</td><td colspan="1" rowspan="1">559 (54.4)</td><td colspan="1" rowspan="1">78 (58.6)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td colspan="1" rowspan="1">190,684 (57.5)</td><td colspan="1" rowspan="1">468 (45.6)</td><td colspan="1" rowspan="1">55 (41.4)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Diabetes, n (%)</td><td colspan="1" rowspan="1">104,426 (31.8)</td><td colspan="1" rowspan="1">313 (30.5)</td><td colspan="1" rowspan="1">46 (34.6)</td><td colspan="1" rowspan="1">.52</td></tr><tr><td colspan="1" rowspan="1">Alcohol abuse, n (%)</td><td colspan="1" rowspan="1">23,084 (7.0)</td><td colspan="1" rowspan="1">454 (44.2)</td><td colspan="1" rowspan="1">51 (38.4)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Tobacco use, n (%)</td><td colspan="1" rowspan="1">56,235 (16.9)</td><td colspan="1" rowspan="1">643 (62.6)</td><td colspan="1" rowspan="1">97 (72.9)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Obesity, n (%)</td><td colspan="1" rowspan="1">138,392 (41.7)</td><td colspan="1" rowspan="1">421 (42.0)</td><td colspan="1" rowspan="1">68 (51.1)</td><td colspan="1" rowspan="1">.08</td></tr><tr><td colspan="1" rowspan="1">AVN, n (%)</td><td colspan="1" rowspan="1">23,138 (7.0)</td><td colspan="1" rowspan="1">215 (20.9)</td><td colspan="1" rowspan="1">35 (26.3)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Surgical complications, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Dislocation</td><td colspan="1" rowspan="1">9456 (2.9)</td><td colspan="1" rowspan="1">82 (8.0)</td><td colspan="1" rowspan="1">9 (6.8)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Infection</td><td colspan="1" rowspan="1">10,254 (3.1)</td><td colspan="1" rowspan="1">116 (11.3)</td><td colspan="1" rowspan="1">11 (8.3)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Mechanical</td><td colspan="1" rowspan="1">6556 (2.0)</td><td colspan="1" rowspan="1">50 (4.9)</td><td colspan="1" rowspan="1">1 (0.8)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">&#160;PPFx</td><td colspan="1" rowspan="1">4828 (1.5)</td><td colspan="1" rowspan="1">28 (2.7)</td><td colspan="1" rowspan="1">2 (2.3)</td><td colspan="1" rowspan="1">.003</td></tr><tr><td colspan="1" rowspan="1">&#160;Revision</td><td colspan="1" rowspan="1">4303 (1.3)</td><td colspan="1" rowspan="1">40 (3.9)</td><td colspan="1" rowspan="1">5 (3.8)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Medical complications, n (%)</td><td colspan="1" rowspan="1">10,132 (3.1)</td><td colspan="1" rowspan="1">47 (4.6)</td><td colspan="1" rowspan="1">6 (4.5)</td><td colspan="1" rowspan="1">.01</td></tr><tr><td colspan="1" rowspan="1">90-d readmission, n (%)</td><td colspan="1" rowspan="1">19,331 (5.8)</td><td colspan="1" rowspan="1">135 (13.2)</td><td colspan="1" rowspan="1">15 (11.3)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Length of stay [d (SD)]</td><td colspan="1" rowspan="1">2.4 (2.4)</td><td colspan="1" rowspan="1">3.7 (4.7)</td><td colspan="1" rowspan="1">2.8 (2.7)</td><td colspan="1" rowspan="1">&lt;.001</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>AVN, avascular necrosis; SD, standard deviation.</p></fn><fn id="tspara0020"><p>Significance defined as &#8804;0.05.</p></fn></table-wrap-foot></table-wrap></p><p id="p0035">Of the 333,038 primary THA cases for osteoarthritis, 1027 (0.31%) patients were identified with active abuse of amphetamines and 133 (0.04%) patients in remission. Those with active amphetamine abuse were younger and more likely to be male (<xref rid="tbl1" ref-type="table">Table&#160;1</xref>). Amphetamine abusers exhibited a higher rate of tobacco and alcohol use and had higher rates of avascular necrosis than nonusers.</p></sec><sec id="sec3"><title>Results</title><p id="p0040">We found that all surgical complications studied were higher in amphetamine abusers (<xref rid="tbl2" ref-type="table">Table&#160;2</xref>). Those with active amphetamine abuse were significantly more likely to experience dislocation (OR 2.96, 95% confidence interval [CI] 2.85-3.07, <italic toggle="yes">P</italic> &lt; .001) and had higher rates of infection (OR 3.99, 95% CI 3.88-4.11, <italic toggle="yes">P</italic> &lt; .001). They were more likely to experience mechanical complications (OR 2.54, 95% CI 2.49-2.59, <italic toggle="yes">P</italic> &lt; .001) and periprosthetic fracture (OR 1.90, 95% CI 1.81-1.99, <italic toggle="yes">P</italic> &lt; .001). Risk of revision was significantly higher for amphetamine abusers (OR 3.09, 95% CI 2.92-3.26, <italic toggle="yes">P</italic> &lt; .001). Medical complications were also higher for those with active amphetamine abuse (OR 1.52, 95% CI 1.45-1.60, <italic toggle="yes">P</italic> &lt; .001). Risk of 90-day readmission postoperatively was also significantly higher for active amphetamine abusers (OR 2.45, 95% CI 2.38-2.52, <italic toggle="yes">P</italic> &lt; .001). Those with active amphetamine abuse had longer length of stay than those without amphetamine abuse (3.70 days &#177; 4.65 days vs 2.41 days &#177; 2.38 days, <italic toggle="yes">P</italic> &lt; .001). Logistic regression analysis controlling for confounding variables is shown in <xref rid="tbl3" ref-type="table">Table&#160;3</xref>. Patients with active amphetamine abuse carried a higher risk of dislocation (OR 1.82, <italic toggle="yes">P</italic> &#8804; .001), infection (OR 2.37, <italic toggle="yes">P</italic> &#8804; .001), mechanical complications (OR 1.64, <italic toggle="yes">P</italic> &#8804; .001), periprosthetic fracture (OR 1.53, <italic toggle="yes">P</italic> &#8804; .05), revision (OR 1.70, <italic toggle="yes">P</italic> &#8804; .001), readmission (OR 1.79, <italic toggle="yes">P</italic> &#8804; .001), as well as medical complications (OR 1.43, <italic toggle="yes">P</italic>&#160;= .02).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table&#160;2</label><caption><p>Comorbidities and complications for stimulant users and those in remission compared to nonstimulant use undergoing primary THA.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Variable</th><th colspan="1" rowspan="1">Stimulant [OR (95% CI)]</th><th colspan="1" rowspan="1">Remission [OR (95% CI)]</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Sex (male)</td><td colspan="1" rowspan="1">1.61 (1.58-1.65)</td><td colspan="1" rowspan="1">1.92 (1.36-2.70)</td></tr><tr><td colspan="1" rowspan="1">Alcohol abuse</td><td colspan="1" rowspan="1">10.60 (10.38-10.82)</td><td colspan="1" rowspan="1">8.32 (5.86-11.80)</td></tr><tr><td colspan="1" rowspan="1">Tobacco use</td><td colspan="1" rowspan="1">8.21 (8.04-8.38)</td><td colspan="1" rowspan="1">13.21 (9.01-19.36)</td></tr><tr><td colspan="1" rowspan="1">AVN</td><td colspan="1" rowspan="1">3.53 (3.44-3.63)</td><td colspan="1" rowspan="1">4.77 (3.24-7.01)</td></tr><tr><td colspan="1" rowspan="1">Surgical complications</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Dislocation</td><td colspan="1" rowspan="1">2.96 (2.85-3.07)</td><td colspan="1" rowspan="1">2.47 (1.26-4.87)</td></tr><tr><td colspan="1" rowspan="1">&#160;Infection</td><td colspan="1" rowspan="1">3.99 (3.88-4.11)</td><td colspan="1" rowspan="1">2.83 (1.53-5.24)</td></tr><tr><td colspan="1" rowspan="1">&#160;Mechanical</td><td colspan="1" rowspan="1">2.54 (2.49-2.59)</td><td colspan="1" rowspan="1">0.37 (0.053-2.69)</td></tr><tr><td colspan="1" rowspan="1">&#160;PPFx</td><td colspan="1" rowspan="1">1.90 (1.81-1.99)</td><td colspan="1" rowspan="1">1.03 (0.26-4.18)</td></tr><tr><td colspan="1" rowspan="1">&#160;Revision</td><td colspan="1" rowspan="1">3.09 (2.92-3.26)</td><td colspan="1" rowspan="1">2.97 (1.22-7.27)</td></tr><tr><td colspan="1" rowspan="1">Medical complications</td><td colspan="1" rowspan="1">1.52 (1.45-1.60)</td><td colspan="1" rowspan="1">1.50 (0.66-3.40)</td></tr><tr><td colspan="1" rowspan="1">90-d readmission</td><td colspan="1" rowspan="1">2.45 (2.38-2.52)</td><td colspan="1" rowspan="1">2.06 (1.20-3.52)</td></tr></tbody></table><table-wrap-foot><fn><p>AVN, avascular necrosis; CI, confidence interval; OR, odds ratio; PPFx, periprosthetic femur fracture.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table&#160;3</label><caption><p>Results from multivariate analysis using logistic regression. Odds ratios reported when adjusting for all comorbidities.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" colspan="1">Predictors</th><th colspan="21" rowspan="1">Complications<hr/></th></tr><tr><th colspan="3" rowspan="1">Dislocation<hr/></th><th colspan="3" rowspan="1">Infection<hr/></th><th colspan="3" rowspan="1">Mechanical<hr/></th><th colspan="3" rowspan="1">PPFx<hr/></th><th colspan="3" rowspan="1">Revision<hr/></th><th colspan="3" rowspan="1">Readmission<hr/></th><th colspan="3" rowspan="1">Medical<hr/></th></tr><tr><th colspan="1" rowspan="1"><italic toggle="yes">&#946;</italic></th><th colspan="1" rowspan="1">aOR (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1"><italic toggle="yes">&#946;</italic></th><th colspan="1" rowspan="1">aOR (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1"><italic toggle="yes">&#946;</italic></th><th colspan="1" rowspan="1">aOR (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1"><italic toggle="yes">&#946;</italic></th><th colspan="1" rowspan="1">aOR (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1"><italic toggle="yes">&#946;</italic></th><th colspan="1" rowspan="1">aOR (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1"><italic toggle="yes">&#946;</italic></th><th colspan="1" rowspan="1">aOR (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1"><italic toggle="yes">&#946;</italic></th><th colspan="1" rowspan="1">aOR (95% CI)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age</td><td colspan="1" rowspan="1">0.002</td><td colspan="1" rowspan="1">1.00 (1.00-1.00)</td><td colspan="1" rowspan="1">.06</td><td colspan="1" rowspan="1">&#8722;0.01</td><td colspan="1" rowspan="1">0.99 (0.98-0.99)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">&#8722;0.01</td><td colspan="1" rowspan="1">0.99 (0.99-0.99)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">1.03 (1.03-1.04)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">&#8722;0.02</td><td colspan="1" rowspan="1">0.98 (0.98-0.99)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">1.01 (1.01-1.01)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">1.03 (1.03-1.03)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">CCI</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.09 (1.08-1.10)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.09 (1.08-1.10)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.06 (1.05-1.07)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.06 (1.05-1.07)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.06 (1.04-1.07)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">1.12 (1.12-1.13)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">1.16 (1.16-1.17)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Sex (male)</td><td colspan="1" rowspan="1">&#8722;0.36</td><td colspan="1" rowspan="1">0.70 (0.66-0.73)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.05 (1.01-1.10)</td><td colspan="1" rowspan="1">.01</td><td colspan="1" rowspan="1">&#8722;0.09</td><td colspan="1" rowspan="1">0.91 (0.67-0.96)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">&#8722;0.40</td><td colspan="1" rowspan="1">0.68 (0.64-0.72)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">&#8722;0.05</td><td colspan="1" rowspan="1">0.95 (0.89-1.01)</td><td colspan="1" rowspan="1">.10</td><td colspan="1" rowspan="1">&#8722;0.09</td><td colspan="1" rowspan="1">0.92 (0.89-0.95)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.27</td><td colspan="1" rowspan="1">1.12 (1.08-1.17)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Diabetes</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.05 (0.10-1.09)</td><td colspan="1" rowspan="1">.06</td><td colspan="1" rowspan="1">.22</td><td colspan="1" rowspan="1">1.25 (1.20-1.30)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.06 (1.01-1.12)</td><td colspan="1" rowspan="1">.03</td><td colspan="1" rowspan="1">&#8722;0.03</td><td colspan="1" rowspan="1">0.97 (0.91-1.03)</td><td colspan="1" rowspan="1">.29</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">1.04 (0.97-1.11)</td><td colspan="1" rowspan="1">.27</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">1.17 1.13-1.21)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1">1.33 (1.27-1.39)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Alcohol abuse</td><td colspan="1" rowspan="1"><bold>0.69</bold></td><td colspan="1" rowspan="1"><bold>1.99 (1.87-2.12)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td colspan="1" rowspan="1">0.44</td><td colspan="1" rowspan="1">1.55 (1.46-1.65)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1"><bold>0.36</bold></td><td colspan="1" rowspan="1"><bold>1.44 (1.32-1.56)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td colspan="1" rowspan="1"><bold>0.94</bold></td><td colspan="1" rowspan="1"><bold>2.57 (2.35-2.80)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td colspan="1" rowspan="1"><bold>0.53</bold></td><td colspan="1" rowspan="1"><bold>1.70 (1.55-1.87)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td colspan="1" rowspan="1"><bold>0.58</bold></td><td colspan="1" rowspan="1"><bold>1.79 (1.71-1.88)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td colspan="1" rowspan="1"><bold>0.30</bold></td><td colspan="1" rowspan="1"><bold>1.35 (1.26-1.45)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td></tr><tr><td colspan="1" rowspan="1">Tobacco use</td><td colspan="1" rowspan="1">0.39</td><td colspan="1" rowspan="1">1.48 (1.40-1.55)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1">1.30 (1.24-1.36)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1">1.34 (1.26-1.43)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1">1.39 (1.29-1.50)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.32</td><td colspan="1" rowspan="1">1.37 (1.28-1.48)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.28</td><td colspan="1" rowspan="1">1.33 (1.28-1.38)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">1.28 (1.22-1.35)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Obesity</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">1.06 (1.01-1.10)</td><td colspan="1" rowspan="1">.01</td><td colspan="1" rowspan="1"><bold>0.54</bold></td><td colspan="1" rowspan="1"><bold>1.71 (1.64-1.78)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1">1.30 (1.23-1.36)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">1.11 (1.04-1.17)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">1.36 (1.28-1.45)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.22</td><td colspan="1" rowspan="1">1.25 (1.21-1.29)</td><td colspan="1" rowspan="1">&lt;.001</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">1.19 (1.14-1.24)</td><td colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Stimulant use</td><td colspan="1" rowspan="1"><bold>0.60</bold></td><td colspan="1" rowspan="1"><bold>1.82 (1.43-2.27)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td colspan="1" rowspan="1"><bold>0.86</bold></td><td colspan="1" rowspan="1"><bold>2.37 (1.93-2.88)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td colspan="1" rowspan="1"><bold>0.49</bold></td><td colspan="1" rowspan="1"><bold>1.64 (1.21-2.16)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td colspan="1" rowspan="1"><bold>0.43</bold></td><td colspan="1" rowspan="1"><bold>1.53 (1.02-2.20)</bold></td><td colspan="1" rowspan="1"><bold>.028</bold></td><td colspan="1" rowspan="1"><bold>0.53</bold></td><td colspan="1" rowspan="1"><bold>1.70 (1.21-2.31)</bold></td><td colspan="1" rowspan="1"><bold>.001</bold></td><td colspan="1" rowspan="1"><bold>0.58</bold></td><td colspan="1" rowspan="1"><bold>1.79 (1.47-2.14)</bold></td><td colspan="1" rowspan="1"><bold>&lt;.001</bold></td><td colspan="1" rowspan="1"><bold>0.36</bold></td><td colspan="1" rowspan="1"><bold>1.43 (1.04-1.91)</bold></td><td colspan="1" rowspan="1"><bold>.02</bold></td></tr><tr><td colspan="1" rowspan="1">Remission</td><td colspan="1" rowspan="1">0.34</td><td colspan="1" rowspan="1">1.41 (0.66-2.65)</td><td colspan="1" rowspan="1">.32</td><td colspan="1" rowspan="1">0.35</td><td colspan="1" rowspan="1">1.42 (0.72-2.55)</td><td colspan="1" rowspan="1">.27</td><td colspan="1" rowspan="1">&#8722;1.52</td><td colspan="1" rowspan="1">0.22 (0.01-0.98)</td><td colspan="1" rowspan="1">.13</td><td colspan="1" rowspan="1">&#8722;0.17</td><td colspan="1" rowspan="1">0.85 (0.14-2.68)</td><td colspan="1" rowspan="1">.82</td><td colspan="1" rowspan="1">0.40</td><td colspan="1" rowspan="1">1.49 (0.52-3.29)</td><td colspan="1" rowspan="1">.39</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">1.36 (0.75-2.28)</td><td colspan="1" rowspan="1">.27</td><td colspan="1" rowspan="1">0.27</td><td colspan="1" rowspan="1">1.31 (0.51-2.75)</td><td colspan="1" rowspan="1">.52</td></tr></tbody></table><table-wrap-foot><fn id="tspara0040"><p>aOR, adjusted odds ratio; CCI, Charlson comorbidity index; CI, confidence interval.</p></fn><fn id="tspara0045"><p>Bold denotes two highest risks of complication per predictor.</p></fn></table-wrap-foot></table-wrap></p><p id="p0045">Amphetamine abusers were more likely to use tobacco (OR 8.21, 95% CI 8.04-8.38, <italic toggle="yes">P</italic> &lt; 001) and alcohol (OR 10.60, 95% CI 10.38-10.82, <italic toggle="yes">P</italic> &lt; .001) compared to nonusers (<xref rid="tbl2" ref-type="table">Table&#160;2</xref>). Alcohol use independently carried a significantly elevated risk of all measured complications when analyzed via logistic regression, including dislocation (OR 1.99, <italic toggle="yes">P</italic> &lt; .001), infection (OR 1.55, <italic toggle="yes">P</italic> &lt; .001), mechanical complications (OR 1.44, <italic toggle="yes">P</italic> &lt; .001), periprosthetic fracture (OR 2.57, <italic toggle="yes">P</italic> &lt; .001), revision (OR 1.70, <italic toggle="yes">P</italic> &lt; .001), readmission (OR 1.79, <italic toggle="yes">P</italic> &lt; .001), and medical complications (OR 1.35, <italic toggle="yes">P</italic> &lt; .001) (<xref rid="tbl3" ref-type="table">Table&#160;3</xref>). Similarly, tobacco use independently carried a significant elevated risk for all measured complications of dislocation (OR 1.48, <italic toggle="yes">P</italic> &lt; .001), infection (OR 1.30, <italic toggle="yes">P</italic> &lt; .001), mechanical complications (OR 1.34, <italic toggle="yes">P</italic> &lt; .001), periprosthetic fracture (OR 1.39, <italic toggle="yes">P</italic> &lt; .001), revision (OR 1.37, <italic toggle="yes">P</italic> &lt; .001), readmission (OR 1.33, <italic toggle="yes">P</italic> &lt; .001), and medical complications (OR 1.28, <italic toggle="yes">P</italic> &lt; .001) (<xref rid="tbl3" ref-type="table">Table&#160;3</xref>).</p><p id="p0050">For those in remission from amphetamine abuse, increased risk of dislocation and infection persisted compared to patients with no history of amphetamine abuse (OR 2.47, 95% CI 1.26-4.87, <italic toggle="yes">P</italic> &lt; .001 and OR 2.83, 95% CI 1.53-5.24, <italic toggle="yes">P</italic> &lt; .001, respectively). Revision rate was also higher (OR 2.97, 95% CI 1.22-7.27, <italic toggle="yes">P</italic> &lt; .001). There was no difference in risk of medical complications (OR 1.50, 95% CI 0.66-3.40). 90-day readmission rate was also increased for those in remission (OR 2.06, 95% CI 1.20-3.52, <italic toggle="yes">P</italic> &lt; .001). Logistic regression found that patients in remission from amphetamine abuse were not at increased risk of dislocation, infection, revision, readmission, or medical complications (<xref rid="tbl3" ref-type="table">Table&#160;3</xref>).</p></sec><sec id="sec4"><title>Discussion</title><p id="p0055">There is a paucity of literature addressing the risk profile of amphetamine abusers who undergo primary THA. We found that primary THA is being performed in patients with active amphetamine abuse and that these patients carried an elevated risk of surgical and medical complications. Amphetamine abusers were more likely to experience infection, and dislocations and were more likely to be readmitted postoperatively or undergo revision. We found that amphetamine abuse carried increased risk of polysubstance abuse with alcohol and/or tobacco, which were both independently associated with increased risk of complications. Patients in remission from amphetamine abuse were also at higher risk of dislocation, infection, revision, and 90-day readmission than nonusers.</p><p id="p0060">Our study found a prevalence of 0.31% recorded active amphetamine abuse in primary THA within our cohort, a number that we suspect may be underreported and expected to increase given trends in amphetamine abuse. As amphetamine abuse continues to rise, understanding surgical risk factors associated with its abuse is paramount in primary THA. From 2016 to 2019, methamphetamine abuse was found to rise by 43%, and the number of adults diagnosed with methamphetamine abuse disorder rose 62% in the same timeframe [<xref rid="bib1" ref-type="bibr">1</xref>]. Furthermore, in a large retrospective study of trauma patients from 2009 to 2018, the rate of methamphetamine abuse quadrupled in this timeframe in patients older than 55 years of age [<xref rid="bib3" ref-type="bibr">3</xref>]. As methamphetamine abuse rises in popularity, particularly among geriatric patients, consideration of amphetamine abuse and its effects on THA outcomes is becoming increasingly relevant. Understanding outcomes following THA in this population will be helpful in counseling patients seeking joint replacement while actively using amphetamines, with emphasis on cessation prior to undergoing THA.</p><p id="p0065">The effect of amphetamine abuse within the arthroplasty realm is limited, with most research being within orthopaedic trauma where in some regions, amphetamine abuse is pervasive. In a retrospective database review from 2008-2018 at a level 1 academic trauma center, of 371 patients who underwent traumatic acetabular open reduction internal fixation, nearly 10% abused methamphetamines [<xref rid="bib4" ref-type="bibr">4</xref>]. This study found that methamphetamine abusers had more than 2 times the reoperation rate at 90 days postoperatively (17% vs 7%), and 1 year postoperatively (25% vs 11%) compared to abstainers, with an adjusted odds ratio of 1 year reoperation of 3.2 (95% CI 1.2-8.5, <italic toggle="yes">P</italic>&#160;= .03). Similarly, our study found an elevated risk of revision for amphetamine abusers following primary THA (OR 1.70, <italic toggle="yes">P</italic> &#8804; .001). Additionally, the study by Zusman, et&#160;al. found an adjusted 1-year survival of native hip following acetabular fractures treated with open reduction internal fixation in methamphetamine abusers of only 55%. As indications for THA expand, with THA often pursued following failed open reduction internal fixation for acetabular fracture as well as acutely for acetabular fracture [<xref rid="bib7" ref-type="bibr">7</xref>], addressing amphetamine abuse and its impact on THA outcomes in the trauma setting is warranted.</p><p id="p0070">This study demonstrates the high-risk profile of amphetamine abuse for THA outcomes, which is similar to risks seen in alcohol misuse and tobacco use. In one study of nationwide claims data assessing outcomes following THA, patients with alcohol misuse had longer LOS (4 days vs 3 days, <italic toggle="yes">P</italic> &lt; .0001) and higher risk of 90-day medical complications (45.94% vs 12.25%; OR, 2.89, <italic toggle="yes">P</italic> &lt; .0001) and 2-year implant-related complications (17.71% vs 8.46%; OR, 1.97, <italic toggle="yes">P</italic> &lt; .0001) [<xref rid="bib8" ref-type="bibr">8</xref>]. Tobacco use, on the other hand, has been shown to carry a higher risk for infection requiring revision surgery (OR 1.54, 95% CI 1.25-1.91) via meta-analysis [<xref rid="bib9" ref-type="bibr">9</xref>], as well as have higher risk for postoperative medical complications and increased mortality [<xref rid="bib10" ref-type="bibr">10</xref>]. This study shows that like alcohol and tobacco use, amphetamine abuse carries profound, independent risk of surgical complications; however, those with amphetamine abuse are also at high risk of concomitant alcohol and tobacco use as well as other high-risk behaviors. Further study analyzing the impact of polysubstance use is needed.</p><p id="p0075">Our study demonstrated no difference in risk of dislocation, infection, revision, and 90-day readmission for patients in remission from amphetamine abuse. This result should be interpreted with caution, as we suspect that these risks do persist independently with amphetamine abuse in remission, but our study possibly underpowered in this regard. Studying the true impact of remission is challenging given the high risk of methamphetamine relapse rate, which has been estimated to be as high as 85% [<xref rid="bib11" ref-type="bibr">11</xref>]. Additional research with a more robust cohort of patients in remission from amphetamine abuse is needed to analyze the change in risk profile between those with active amphetamine abuse and those in remission to better understand whether these risk factors are modifiable with methamphetamine cessation.</p><p id="p0080">There are limitations of this study, particularly in its retrospective database nature, which may lead to potential selection bias as not all arthroplasty cases are encompassed within this database. Furthermore, the PearlDiver database, while broad and comprehensive, relies on accurate manual coding by practitioners, which may introduce a component of coding bias. We chose to include ICD-10 codes to eliminate mismatches in coding found in the previous ICD-9 system. As such, cases prior to 2015 were not included and follow-up was limited at 6&#160;years. Amphetamine abuse-type stimulant codes were utilized for this study, excluding codes for other stimulants such as cocaine and caffeine and amphetamine-type stimulants taken in a prescribed manner, with the aim to select solely for illicit amphetamine abuse or misuse. This cohort may also include those who abuse prescription amphetamines illicitly or in a disordered manner rather than solely address methamphetamine abuse independently. Additionally, as discussed, it is suspected that amphetamine abuse may be underreported and as such underestimate postoperative risks. Furthermore, with the high rate of relapse with methamphetamine abuse, those carrying relapse diagnoses may in fact not truly be in remission. With the PearlDiver database encompassing all insurance claims data with the exception of Kaiser and TRICARE, it is an optimal database to generalize data. Even so, this remains the first and largest cohort to address amphetamine abuse within primary THA outcomes and illuminates the high-risk profile of amphetamine abuse.</p></sec><sec id="sec5"><title>Conclusions</title><p id="p0085">Patients actively using amphetamine are at high risk of postoperative surgical and medical complications following THA. The risks from amphetamine abuse are similar to those seen with alcohol misuse and tobacco use. We recommend consideration of these risks prior to undergoing primary THA in this patient population.</p></sec><sec id="sec6"><title>Conflicts of interest</title><p id="p0090">The authors declare there are no conflicts of interest.</p><p id="p0095">For full disclosure statements refer to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.artd.2024.101372" id="intref0010">https://doi.org/10.1016/j.artd.2024.101372</ext-link>.</p></sec><sec id="sec7"><title>CRediT authorship contribution statement</title><p id="p0100"><bold>Mackenzie Kelly:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. <bold>Thomas Huff:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Resources, Methodology, Investigation, Formal analysis, Conceptualization. <bold>Kathryn Schabel:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Resources, Methodology, Investigation, Formal analysis, Conceptualization. <bold>Jung Yoo:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. <bold>Elizabeth Lieberman:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. <bold>Ryland Kagan:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Supervision, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>B.</given-names></name><name name-style="western"><surname>Compton</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Einstein</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>N.D.</given-names></name></person-group><article-title>Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults</article-title><source>JAMA Psychiatry</source><volume>78</volume><year>2021</year><fpage>1329</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2021.2588</pub-id><pub-id pub-id-type="pmid">34550301</pub-id><pub-id pub-id-type="pmcid">PMC8459304</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Winkelman</surname><given-names>T.N.A.</given-names></name><name name-style="western"><surname>Admon</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shippee</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Bart</surname><given-names>G.</given-names></name></person-group><article-title>Evaluation of amphetamine-related hospitalizations and associated clinical outcomes and costs in the United States</article-title><source>JAMA Netw Open</source><volume>1</volume><year>2018</year><object-id pub-id-type="publisher-id">e183758</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.3758</pub-id><pub-id pub-id-type="pmcid">PMC6324446</pub-id><pub-id pub-id-type="pmid">30646256</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Benham</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Rooney</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>R.Y.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sise</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>The rising tide of methamphetamine use in elderly trauma patients</article-title><source>Am J Surg</source><volume>221</volume><year>2021</year><fpage>1246</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1016/j.amjsurg.2021.02.030</pub-id><pub-id pub-id-type="pmid">33707080</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Zusman</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Woelber</surname><given-names>E.</given-names></name><name name-style="western"><surname>McKibben</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Gallacher</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Friess</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Methamphetamines and acetabular reoperation rates: poor outcomes from the front lines</article-title><source>J&#160;Orthop Trauma</source><volume>35</volume><year>2021</year><fpage>e491</fpage><lpage>e495</lpage><pub-id pub-id-type="doi">10.1097/BOT.0000000000002133</pub-id><pub-id pub-id-type="pmid">34469420</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Githens</surname><given-names>T.</given-names></name><name name-style="western"><surname>DeBaun</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Goodnough</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Lichstein</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Rates of perioperative complications among patients undergoing orthopedic trauma surgery despite having positive results for methamphetamine</article-title><source>Orthopedics</source><volume>42</volume><year>2019</year><fpage>192</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.3928/01477447-20190523-01</pub-id><pub-id pub-id-type="pmid">31136677</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Quatman</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Phieffer</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>T.V.</given-names></name></person-group><article-title>30-day adverse events, length of stay and re-admissions following surgical management of pelvic/acetabular fractures</article-title><source>J&#160;Clin Orthop Trauma</source><volume>10</volume><year>2019</year><fpage>890</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1016/j.jcot.2019.02.010</pub-id><pub-id pub-id-type="pmid">31528063</pub-id><pub-id pub-id-type="pmcid">PMC6739240</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Working</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Friess</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>R.</given-names></name></person-group><article-title>Risk of revision and complications after total hip arthroplasty for acute treatment of acetabular fracture</article-title><source>J&#160;Arthroplasty</source><volume>38</volume><year>2023</year><fpage>S270</fpage><lpage>S275.e1</lpage><pub-id pub-id-type="doi">10.1016/j.arth.2023.05.038</pub-id><pub-id pub-id-type="pmid">37257790</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Horn</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Vakharia</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Mont</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Erez</surname><given-names>O.</given-names></name></person-group><article-title>The association of alcohol use disorder with perioperative complications following primary total hip arthroplasty</article-title><source>Hip Pelvis</source><volume>33</volume><year>2021</year><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.5371/hp.2021.33.4.231</pub-id><pub-id pub-id-type="pmid">34938693</pub-id><pub-id pub-id-type="pmcid">PMC8654594</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Bojan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Perni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prokopovich</surname><given-names>P.</given-names></name></person-group><article-title>Systematic review and meta-analysis of tobacco use as a risk factor for Prosthetic joint infection after total hip replacement</article-title><source>Arthroplast Today</source><volume>6</volume><year>2020</year><fpage>959</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1016/j.artd.2020.07.011</pub-id><pub-id pub-id-type="pmid">33385034</pub-id><pub-id pub-id-type="pmcid">PMC7772455</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Matharu</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Mouchti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Twigg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Delmestri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Judge</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The effect of smoking on outcomes following primary total hip and knee arthroplasty: a population-based cohort study of 117,024 patients</article-title><source>Acta Orthop</source><volume>90</volume><year>2019</year><fpage>559</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1080/17453674.2019.1649510</pub-id><pub-id pub-id-type="pmid">31370730</pub-id><pub-id pub-id-type="pmcid">PMC6844375</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Terry</surname><given-names>D.</given-names></name><name name-style="western"><surname>Peck</surname><given-names>B.</given-names></name></person-group><article-title>The experience of methamphetamine use disorder and the negative consequences of relapse - a qualitative study</article-title><source>J Addict Dis</source><volume>42</volume><year>2023</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1080/10550887.2023.2165870</pub-id><pub-id pub-id-type="pmid">36659876</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary Data</title><p id="p0105">
<supplementary-material content-type="local-data" id="ec1" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Lieberman</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="ec2" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Kelly</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="ec3" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Huff</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc3.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="ec4" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Yoo</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc4.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="ec5" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Kagan</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc5.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="ec6" position="float" orientation="portrait"><caption><title>Conflict of Interest Statement for Schabel</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc6.pdf" position="float" orientation="portrait"/></supplementary-material>
</p></sec><sec id="appsec2"><title>Appendix</title><p id="p0110">
<table-wrap position="anchor" id="tblS1" orientation="portrait"><label>Appendix 1</label><caption><p>ICD-10 Procedure and diagnosis codes used for inclusion.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Procedure</th><th colspan="1" rowspan="1">Procedure codes</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Primary THA</td><td colspan="1" rowspan="1">ICD-10-P-0SR9019, ICD-10-P-0SR901A, ICD-10-P-0SR901Z, ICD-10-P-0SR9029, ICD-10-P-0SR902A, ICD-10-P-0SR902Z, ICD-10-P-0SR9039, ICD-10-P-0SR903A, ICD-10-P-0SR903Z, ICD-10-P-0SR9049, ICD-10-P-0SR904A, ICD-10-P-0SR904Z, ICD-10-P-0SR9069, ICD-10-P-0SR906A, ICD-10-P-0SR906Z, ICD-10-P-0SRB019, ICD-10-P-0SRB01A, ICD-10-P-0SRB01Z, ICD-10-P-0SRB029, ICD-10-P-0SRB02A, ICD-10-P-0SRB02Z, ICD-10-P-0SRB039, ICD-10-P-0SRB03A, ICD-10-P-0SRB03Z, ICD-10-P-0SRB049, ICD-10-P-0SRB04A, ICD-10-P-0SRB04Z, ICD-10-P-0SRB069, ICD-10-P-0SRB06A, ICD-10-P-0SRB06Z</td></tr><tr><td colspan="1" rowspan="1">Revision</td><td colspan="1" rowspan="1">ICD-10-P-0SP908Z, ICD-10-P-0SP909Z, ICD-10-P-0SP90BZ, ICD-10-P-0SP90EZ, ICD-10-P-0SP90JZ, ICD-10-P-0SP90KZ, ICD-10-P-0SPA0JZ, ICD-10-P-0SPB08Z, ICD-10-P-0SPB09Z, ICD-10-P-0SPB0BZ, ICD-10-P-0SPB0EZ, ICD-10-P-0SPB0JZ, ICD-10-P-0SPB0KZ, ICD-10-P-0SPE0JZ, ICD-10-P-0SPR0JZ, ICD-10-P-0SPS0JZ</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Diagnosis</th><th colspan="1" rowspan="1">Diagnosis Codes</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Obesity</td><td colspan="1" rowspan="1">ICD-10-D-E6601, ICD-10-D-E6609, ICD-10-D-E661, ICD-10-D-E662, ICD-10-D-E668, ICD-10-D-E669</td></tr><tr><td colspan="1" rowspan="1">Tobacco use</td><td colspan="1" rowspan="1">ICD-10-D-Z720, ICD-10-D-Z716, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F17290">F17290</ext-link></td></tr><tr><td colspan="1" rowspan="1">Alcohol use</td><td colspan="1" rowspan="1">ICD-9-D-30390, ICD-9-D-30392, ICD-9-D-30391, ICD-9-D-30502, ICD-9-D-30500, ICD-9-D-30501, ICD-10-D-F1020, ICD-10-D-F1010</td></tr><tr><td colspan="1" rowspan="1">Avascular necrosis</td><td colspan="1" rowspan="1">ICD-9-D-73342, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M87051">M87051</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M87052">M87052</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M87059">M87059</ext-link>, ICD-10-D-M87151, ICD-10-D-M87152, ICD-10-D-M87159, ICD-10-D-M87251, ICD-10-D-M87252, ICD-10-D-M87256, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M87351">M87351</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M87352">M87352</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M87353">M87353</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M87851">M87851</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M87852">M87852</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="M87859">M87859</ext-link></td></tr><tr><td colspan="1" rowspan="1">Prosthetic dislocation</td><td colspan="1" rowspan="1">ICD-10-D-T84020A, ICD-10-D-T84020D, ICD-10-D-T84021A, ICD-10-D-T84021D</td></tr><tr><td colspan="1" rowspan="1">Periprosthetic joint infection</td><td colspan="1" rowspan="1">ICD-10-D-T8451XA, ICD-10-D-T8451XD, ICD-10-D-T8452XA, ICD-10-D-T8452XD</td></tr><tr><td colspan="1" rowspan="1">Mechanical complications</td><td colspan="1" rowspan="1">ICD-10-D-T84030A, ICD-10-D-T84030D, ICD-10-D-T84030S, ICD-10-D-T84031A, ICD-10-D-T84031D, ICD-10-D-T84031S, ICD-10-D-T84050A, ICD-10-D-T84050D, ICD-10-D-T84050S, ICD-10-D-T84051A, ICD-10-D-T84051D, ICD-10-D-T84051S, ICD-10-D-T84060A, ICD-10-D-T84060D, ICD-10-D-T84060S, ICD-10-D-T84061A, ICD-10-D-T84061D, ICD-10-D-T84061S, ICD-10-D-T84090A, ICD-10-D-T84090D, ICD-10-D-T84091A, ICD-10-D-T84091D, ICD-10-D-T84091S</td></tr><tr><td colspan="1" rowspan="1">Periprosthetic fracture</td><td colspan="1" rowspan="1">ICD-10-D-M9701XA, ICD-10-D-M9702XA</td></tr><tr><td colspan="1" rowspan="1">Medical complications</td><td colspan="1" rowspan="1">ICD-10-D-I9788, ICD-10-D-D65, ICD-9-D-48239, ICD-10-D-I9789, ICD-10-D-I21A1, ICD-10-D-J9600, ICD-9-D-481, ICD-10-D-I21A9, ICD-9-D-483, ICD-9-D-4828, ICD-10-D-I2129, ICD-9-D-4829, ICD-10-D-J95859, ICD-10-D-A419, ICD-10-D-J160, ICD-9-D-5849, ICD-9-D-41072, ICD-10-D-I236, ICD-10-D-J13, ICD-10-D-I237, ICD-9-D-4821, ICD-10-D-I2121, ICD-9-D-48231, ICD-10-D-I238, ICD-10-D-I97790, ICD-10-D-J95851, ICD-9-D-41070, ICD-9-D-48232, ICD-9-D-41071, ICD-9-D-5845, ICD-9-D-4824, ICD-10-D-J17, ICD-9-D-48230, ICD-10-D-J168, ICD-9-D-4822, ICD-9-D-4823, ICD-10-D-I231, ICD-10-D-I230, ICD-9-D-51884, ICD-10-D-I235, ICD-10-D-I234, ICD-10-D-I233, ICD-9-D-48249, ICD-10-D-I232, ICD-9-D-45384, ICD-9-D-45385, ICD-9-D-45382, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="I82629">I82629</ext-link>, ICD-9-D-45383, ICD-10-D-J15211, ICD-10-D-J15212, ICD-9-D-45381, ICD-9-D-51881, ICD-9-D-4838, ICD-9-D-45389, ICD-9-D-45387, ICD-9-D-45386, ICD-9-D-99802, ICD-9-D-48242, ICD-10-D-I228, ICD-9-D-41060, ICD-9-D-4830, ICD-9-D-41061, ICD-9-D-99800, ICD-9-D-4831, ICD-9-D-41062, ICD-9-D-99801, ICD-9-D-48240, ICD-10-D-I229, ICD-9-D-48241, ICD-10-D-I222, ICD-10-D-I221, ICD-9-D-41052, ICD-9-D-99731, ICD-10-D-I220, ICD-9-D-99732, ICD-10-D-T8110XA, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="I82619">I82619</ext-link>, ICD-9-D-99739, ICD-10-P-0BH18EZ, ICD-10-D-I2109, ICD-10-D-N170, ICD-10-D-I2102, ICD-10-P-0BH17EZ, ICD-10-D-I219, ICD-10-D-I2101, ICD-9-D-41050, ICD-10-D-I214, ICD-10-D-N178, ICD-9-D-41051, ICD-10-D-N179, ICD-9-D-41042, ICD-10-D-I213, ICD-10-D-T8119XA, ICD-9-D-41041, ICD-9-D-45340, ICD-9-D-45341, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="I82609">I82609</ext-link>, ICD-10-D-J150, ICD-10-D-I2119, ICD-10-D-J151, ICD-10-D-T8112XA, ICD-9-D-41519, ICD-10-D-I97710, ICD-10-D-J95822, ICD-10-D-I2111, ICD-10-D-J1520, ICD-10-D-J158, ICD-10-D-J159, ICD-10-D-J156, ICD-10-D-J157, ICD-10-D-J95821, ICD-10-D-J154, ICD-10-D-J155, ICD-10-D-J153, ICD-9-D-41040, ICD-9-D-41512, ICD-9-D-41513, ICD-10-D-I8291, ICD-10-D-J1529, ICD-10-D-J9690, ICD-9-D-51853, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="I82409">I82409</ext-link>, ICD-9-D-51851, ICD-9-D-51852, ICD-9-D-41030, ICD-9-D-41031, ICD-9-D-41032, ICD-10-D-J951, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="I82290">I82290</ext-link>, ICD-10-D-I469, ICD-10-D-T883XXA, ICD-9-D-48289, ICD-9-D-48283, ICD-9-D-48282, ICD-9-D-48284, ICD-9-D-4109, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="I82419">I82419</ext-link>, ICD-10-D-J9620, ICD-9-D-4108, ICD-9-D-48281, ICD-9-D-4107, ICD-9-D-4106, ICD-9-D-41021, ICD-9-D-4105, ICD-9-D-41022, ICD-9-D-4104, ICD-9-D-4103, ICD-9-D-41020, ICD-10-D-I2699, ICD-9-D-5770, ICD-9-D-4101, ICD-9-D-4102, ICD-10-D-I82A19, ICD-10-D-I2692, ICD-9-D-9971, ICD-10-D-I824Y9, ICD-10-D-I82B19, ICD-10-D-I2690, ICD-9-D-41091, ICD-9-D-41090, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="I82890">I82890</ext-link>, ICD-10-D-I82C19, ICD-9-D-41010, ICD-9-D-41011, ICD-10-D-J952, ICD-9-D-99591, ICD-9-D-41012, ICD-10-D-J953, ICD-9-D-4539, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="I82429">I82429</ext-link>, ICD-9-P-9604, ICD-10-D-J9588, ICD-9-D-99586, ICD-10-D-J9589, ICD-10-D-K859, ICD-10-D-J181, ICD-9-D-41080, ICD-9-D-4275, ICD-9-D-41082, ICD-9-D-41081, ICD-10-D-T8111XA, ICD-9-D-41000, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="I82439">I82439</ext-link>, ICD-9-D-2866, ICD-9-D-41001, ICD-9-D-41002</td></tr><tr><td colspan="1" rowspan="1">Stimulant use</td><td colspan="1" rowspan="1">ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15120">F15120</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15121">F15121</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15122">F15122</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15129">F15129</ext-link>, ICD-10-D-F1513, ICD-10-D-F1514, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15150">F15150</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15151">F15151</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15159">F15159</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15180">F15180</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15181">F15181</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15182">F15182</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15188">F15188</ext-link>, ICD-10-D-F1519, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15220">F15220</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15221">F15221</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15222">F15222</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15229">F15229</ext-link>, ICD-10-D-F1523, ICD-10-D-F1524, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15250">F15250</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15251">F15251</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15259">F15259</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15280">F15280</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15281">F15281</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15282">F15282</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15288">F15288</ext-link>, ICD-10-D-F1529, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15920">F15920</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15921">F15921</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15922">F15922</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15929">F15929</ext-link>, ICD-10-D-F1593, ICD-10-D-F1594, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15950">F15950</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15951">F15951</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15959">F15959</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15980">F15980</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15981">F15981</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15982">F15982</ext-link>, ICD-10-D-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="F15988">F15988</ext-link>, ICD-10-D-F1599</td></tr><tr><td colspan="1" rowspan="1">Remission</td><td colspan="1" rowspan="1">ICD-10-D-F1511, ICD-10-D-F1521</td></tr></tbody></table></table-wrap></p></sec></back></article></pmc-articleset>